We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

10 hedge funds and large institutions have $3.45M invested in Evoke Pharma in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

197% more capital invested

Capital invested by funds: $1.16M → $3.45M (+$2.29M)

43% more funds holding

Funds holding: 7 → 10 (+3)

4.2% more ownership

Funds ownership: 2.56% → 6.75% (+4.2%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
10
Holders Change
+3
Holders Change %
+42.86%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$2.31M
2
SC
Sophrosyne Capital
New York
+$485K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$110K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$101K
5
Citigroup
Citigroup
New York
+$20K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$178K
2
ARTA
A.R.T. Advisors
New York
-$83K
3
TC
TFS Capital
Pennsylvania
-$41.4K
4
Bank of America
Bank of America
North Carolina
-$9.98K

EVOK Hedge Fund Activity: Q1 2014 in Review

10 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2014, worth a combined $3.45M — up 197% from $1.16M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EVOK positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $2.31M. The largest seller was Morgan Stanley, cutting an estimated $178K.

  • 10 institutional investors held Evoke Pharma (EVOK) as of Q1 2014, up from 7 in Q4 2013.
  • Funds reported $3.45M of Evoke Pharma stock for Q1 2014, up 197% quarter-over-quarter.
  • 5 funds opened new Evoke Pharma positions in Q1 2014 and 1 closed out, a net change of +4 holders.
  • The largest Evoke Pharma buyer in Q1 2014 was Opaleye Management, an estimated $2.31M added.
  • The largest Evoke Pharma seller in Q1 2014 was Morgan Stanley, an estimated $178K sold.

Based on aggregated 13F filings for Q1 2014.